Robert C. Doebele
0000-0001-6728-6857
Publication & Citation Trends
Publications
0 total
EGFR suppression and drug-induced potentiation are widespread features of oncogenic RTK fusions
Cited by 0
Semantic Scholar
Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes
Cited by 1
Semantic Scholar
Efficacy and safety of pralsetinib in patients with advanced RET -fusion-positive NSCLC: Final data from the phase 1/2 ARROW study.
Cited by 3
Semantic Scholar
Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results
Cited by 5
Semantic Scholar
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.
Cited by 1
Semantic Scholar
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer.
Cited by 2
Semantic Scholar
Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer OA
Cited by 2
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(390)
Cancer Genomics and Diagnostics
(134)
Lung Cancer Research Studies
(102)
Colorectal Cancer Treatments and Studies
(86)
RNA modifications and cancer
(60)
Affiliations
Hospital for Special Surgery
Argonne National Laboratory
Barnes-Jewish Hospital
Universidade Federal do Rio Grande do Sul
St. Jude Children's Research Hospital